{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:13:43Z","timestamp":1792844023799,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Innovation is a hallmark of organ, tissue, and cell transplantation. The development of new treatments derived from these substances of human origin (SoHO) has rapidly evolved in recent years. Despite the great benefits that these innovative therapies could bring to patients, significant difficulties have arisen in making them equitably and widely accessible. Herein, we identify and address 4 challenges to promote innovation in this field in a collaborative, sustainable, and transparent manner and propose some concrete solutions applicable to SoHO-derived treatments, ranging from cell therapies to solid organ transplantation. Regulators, health policymakers, and government officials are recommended to incorporate specific elements into the regulatory frameworks of their respective jurisdictions, although regulatory convergence and equivalent quality and safety standards applicable to SoHO at a global level would be needed. An innovation-driven regulatory environment, respectful with the human origin and in accordance with the altruistic donation of SoHO, should be encouraged to improve the safety, effectiveness, accessibility, and affordability of SoHO and to promote collaboration between countries and between public and private sectors. This overview is the outcome of a working group focused on \u201cInnovation in the donation and clinical application of SoHO\u201d as part of the international Summit \u201cTowards Global Convergence in Transplantation: Sufficiency, Transparency and Oversight\u201d convened by the Organizaci\u00f3n Nacional de Trasplantes under the Spanish Presidency of the Council of the European Union in November 2023 and cosponsored by the Council of Europe, the World Health Organization, the Transplantation Society, and the European Society for Organ Transplantation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000005169","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T21:00:24Z","timestamp":1729630824000},"page":"36-47","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived Therapies"],"prefix":"10.1097","volume":"109","author":[{"given":"Natividad","family":"Cuende","sequence":"first","affiliation":[{"name":"Andalusian Transplant Coordination, Servicio Andaluz de Salud, Sevilla, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G.","family":"Tullius","sequence":"additional","affiliation":[{"name":"Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Izeta","sequence":"additional","affiliation":[{"name":"Donostia University Hospital and Biogipuzkoa Health Research Institute, Advanced Therapies Unit, Donostia-San Sebastian, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Plattner","sequence":"additional","affiliation":[{"name":"Department Blood, Tissue and Vigilance, Federal Office for Safety in Health Care, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6rgel, MSc","sequence":"additional","affiliation":[{"name":"Deutsche Gesellschaft f\u00fcr Gewebetransplantation mbH, Gemeinn\u00fctzige Gesellschaft, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Ciccocioppo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi and University of Verona, Verona, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Correa-Rocha","sequence":"additional","affiliation":[{"name":"Laboratorio de Inmuno-regulaci\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1on (IISGM), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey B. C.","family":"Koh","sequence":"additional","affiliation":[{"name":"Infection and Immunity CAG, St George\u2019s Hospital and Medical School, London, United Kingdom."},{"name":"Cell and Gene Therapy Facility, Blood Services Group, Health Sciences Authority, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Centro Nazionale Sangue, Istituto Superiore di Sanit\u00e0, Roma, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel E.","family":"Gondolesi","sequence":"additional","affiliation":[{"name":"General Surgery, Liver, Pancreas and Intestinal Transplant, Hospital Universitario Fundaci\u00f3n Favaloro, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"ten Ham","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Economics, Julius Center, University Medical Center Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Porte","sequence":"additional","affiliation":[{"name":"Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Hern\u00e1ndez-Maraver","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Nacional de Trasplantes, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.","family":"Hawthorne","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Sydney, Westmead Institute for Medical Research, Westmead, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-L\u2019Hospitalet, Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Surgery, Abdominal Organ Transplant Program, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f6rje","family":"Haraldsson","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Ascher","sequence":"additional","affiliation":[{"name":"Department of Surgery, Transplantation, University of California, San Francisco, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Dominguez-Gil","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n Nacional de Trasplantes, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel C.","family":"Oniscu","sequence":"additional","affiliation":[{"name":"Transplantation Division, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"R1-20241224","article-title":"International report on organ donation and transplantation activities.","year":"2022"},{"key":"R2-20241224","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nbt.3889","article-title":"The promise of organ and tissue preservation to transform medicine.","volume":"35","author":"Giwa","year":"2017","journal-title":"Nat Biotechnol"},{"key":"R3-20241224"},{"key":"R4-20241224","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcyt.2018.09.010","article-title":"Cell, tissue and gene products with marketing authorization in 2018 worldwide.","volume":"20","author":"Cuende","year":"2018","journal-title":"Cytotherapy"},{"key":"R5-20241224","doi-asserted-by":"crossref","first-page":"e56661","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies: can we avoid a catastrophic second valley of death?","volume":"24","author":"De Luca","year":"2023","journal-title":"EMBO Rep"},{"key":"R6-20241224"},{"key":"R7-20241224"},{"key":"R8-20241224"},{"key":"R9-20241224"},{"key":"R10-20241224","doi-asserted-by":"crossref","first-page":"e1466","DOI":"10.1097\/TXD.0000000000001466","article-title":"Tissue and cell donation: recommendations from an international consensus forum.","volume":"9","author":"S\u00e1nchez-Iba\u00f1ez","year":"2023","journal-title":"Transplant Direct"},{"key":"R11-20241224"},{"key":"R12-20241224"},{"key":"R13-20241224"},{"key":"R14-20241224","doi-asserted-by":"crossref","first-page":"557","DOI":"10.15252\/embr.201540070","article-title":"Access to human tissues for research and product development: from EU regulation to alarming legal developments in Belgium.","volume":"16","author":"Pirnay","year":"2015","journal-title":"EMBO Rep"},{"key":"R15-20241224","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/TP.0000000000004527","article-title":"Addressing risks derived from the commodification of substances of human origin: a European proposal applicable worldwide.","volume":"107","author":"Cuende","year":"2023","journal-title":"Transplantation"},{"key":"R16-20241224"},{"key":"R17-20241224"},{"key":"R18-20241224","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jimd.12605","article-title":"Development of medicines for rare diseases and inborn errors of metabolism: toward novel public-private partnerships.","volume":"46","author":"Rosenberg","year":"2023","journal-title":"J Inherit Metab Dis"},{"key":"R19-20241224","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcyt.2016.03.292","article-title":"Cell-based product classification procedure: what can be done differently to improve decisions on borderline products?","volume":"18","author":"Izeta","year":"2016","journal-title":"Cytotherapy"},{"key":"R20-20241224"},{"key":"R21-20241224"},{"key":"R22-20241224","doi-asserted-by":"crossref","first-page":"eabm7190","DOI":"10.1126\/scitranslmed.abm7190","article-title":"Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs.","volume":"14","author":"Wang","year":"2022","journal-title":"Sci Transl Med"},{"key":"R23-20241224","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5966\/sctm.2011-0064","article-title":"Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation?","volume":"1","author":"Cuende","year":"2012","journal-title":"Stem Cells Transl. Med"},{"key":"R24-20241224","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41409-021-01463-y","article-title":"The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001.","volume":"57","author":"Trias","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R25-20241224","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jcyt.2022.09.002","article-title":"Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.","volume":"24","author":"Thielen","year":"2022","journal-title":"Cytotherapy"},{"key":"R26-20241224","doi-asserted-by":"crossref","first-page":"eaag0426","DOI":"10.1126\/scitranslmed.aag0426","article-title":"Marketing of unproven stem cell-based interventions: a call to action.","volume":"9","author":"Sipp","year":"2017","journal-title":"Sci Transl Med"},{"key":"R27-20241224","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3324\/haematol.2013.086231","article-title":"When the best is the enemy of the good: the case of bone-marrow mononuclear cells to treat ischemic syndromes.","volume":"98","author":"Cuende","year":"2013","journal-title":"Haematologica"},{"key":"R30-20241224"},{"key":"R31-20241224"},{"key":"R32-20241224"},{"key":"R33-20241224"},{"key":"R34-20241224"},{"key":"R35-20241224","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R36-20241224"},{"key":"R37-20241224","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations.","volume":"374","author":"McCulloch","year":"2009","journal-title":"Lancet"},{"key":"R38-20241224","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40545-021-00311-0","article-title":"Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?","volume":"14","author":"Ronco","year":"2021","journal-title":"J Pharm Policy Pract"},{"key":"R39-20241224","author":"Liu"},{"key":"R40-20241224","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drudis.2021.09.001","article-title":"Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues.","volume":"27","author":"Young","year":"2022","journal-title":"Drug Discov Today"},{"key":"R41-20241224","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","article-title":"Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system.","volume":"22","author":"Quinn","year":"2019","journal-title":"Value Health"},{"key":"R42-20241224","doi-asserted-by":"crossref","first-page":"729847","DOI":"10.3389\/fpubh.2021.729847","article-title":"Do advanced therapies have a future in the low- and middle-income countries\u2014the case of Bulgaria, Romania, and Poland.","volume":"9","author":"Kamusheva","year":"2021","journal-title":"Front Public Health"},{"key":"R43-20241224"},{"key":"R44-20241224","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting.","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"key":"R45-20241224","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/hum.2021.168","article-title":"Is hospital exemption an alternative or a bridge to European medicines agency for developing academic chimeric antigen receptor T-cell in Europe? Our experience with ARI-0001.","volume":"32","author":"Juan","year":"2021","journal-title":"Hum Gene Ther"},{"key":"R46-20241224","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14737167.2023.2197214","article-title":"Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal.","volume":"23","author":"Toumi","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R47-20241224","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12913-023-09494-5","article-title":"How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?","volume":"23","author":"Drummond","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"R49-20241224","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10198-021-01276-2","article-title":"Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.","volume":"23","author":"Gon\u00e7alves","year":"2022","journal-title":"Eur J Health Econ"},{"key":"R50-20241224"},{"key":"R51-20241224"},{"key":"R52-20241224","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.stem.2023.07.004","article-title":"Regulation of advanced therapies in Europe: are we on the right track?","volume":"30","author":"Izeta","year":"2023","journal-title":"Cell Stem Cell"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T12:00:58Z","timestamp":1735041658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005169","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}